ITEM VIEW

Tuberculosis in oncology patients

dc.contributor.authorStefan D.C.
dc.contributor.authorKruis A.L.
dc.contributor.authorSchaaf H.S.
dc.contributor.authorWessels G.
dc.date.accessioned2011-05-15T16:15:32Z
dc.date.available2011-05-15T16:15:32Z
dc.date.issued2008
dc.identifier.citationAnnals of Tropical Paediatrics
dc.identifier.citation28
dc.identifier.citation2
dc.identifier.issn02724936
dc.identifier.other10.1179/146532808X302125
dc.identifier.urihttp://hdl.handle.net/10019.1/13381
dc.description.abstractBackground: There is a dearth of studies addressing the incidence and clinical presentation of tuberculosis (TB) in children with cancer. Aim: To evaluate the incidence of TB in paediatric oncology patients at Tygerberg Hospital, located in a Cape Town area of high TB prevalence, and to describe the clinical characteristics of the disease in this particular group of patients whose treatment typically suppresses their immune response. Methods: We reviewed the records of 625 paediatric oncology patients admitted from 1 January 1991 to 31 December 2005. Of these, 87 received treatment for TB; however, only 57 cases had sufficient data to support a diagnosis of TB and only these were used for further analysis. Results: In the children with TB, acute lymphoblastic leukaemia (ALL) was the most common malignancy (13/57, 22.8%). The incidence of TB in the study group was 9117/100,000/year, which is 22 times higher than the overall TB incidence reported in children from a similar background. Importantly, 47% of the active infections appeared in the 1st 5 months of chemotherapy, suggesting reactivation of latent TB. Conclusions: Identifying latent TB in our patients and providing prophylactic treatment during the initial months of chemotherapy might have prevented disease progression in these cases. Routine screening of paediatric oncology patients for latent TB infection and exclusion of active disease prior to initiation of cancer therapy might be indicated in TB-endemic areas. © 2008 The Liverpool School of Tropical Medicine.
dc.subjectantineoplastic agent
dc.subjectethambutol
dc.subjectethionamide
dc.subjectisoniazid
dc.subjectpyrazinamide
dc.subjectrifampicin
dc.subjecttuberculostatic agent
dc.subjectacute lymphoblastic leukemia
dc.subjectadolescent
dc.subjectcancer chemotherapy
dc.subjectcancer patient
dc.subjectchild
dc.subjectchildhood cancer
dc.subjectclinical feature
dc.subjectdisease course
dc.subjectdrug potentiation
dc.subjectfemale
dc.subjecthematologic malignancy
dc.subjecthuman
dc.subjectincidence
dc.subjectinfant
dc.subjectliver function test
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical record review
dc.subjectmultiple cycle treatment
dc.subjectprevalence
dc.subjectreview
dc.subjectside effect
dc.subjectsolid tumor
dc.subjectSouth Africa
dc.subjecttuberculosis
dc.subjecttuberculosis control
dc.subjectAdolescent
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectFemale
dc.subjectHumans
dc.subjectIncidence
dc.subjectInfant
dc.subjectInfant, Newborn
dc.subjectMale
dc.subjectNeoplasms
dc.subjectOpportunistic Infections
dc.subjectPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subjectSouth Africa
dc.subjectTuberculosis
dc.titleTuberculosis in oncology patients
dc.typeReview
dc.description.versionReview


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW